What is Amprion?
Amprion operates as a global leader in the advancement of diagnostic solutions for neurodegenerative disorders, specifically through its pioneering seed amplification testing methodology. The company's intellectual property portfolio is centered on the SAAmplify-SYN biomarker test, which serves as a vital tool for identifying synucleinopathies linked to Parkinson's disease, Lewy body dementia, and Alzheimer's disease. By providing clinicians with precise diagnostic data, Amprion is effectively bridging the gap between early detection and therapeutic intervention. Beyond its diagnostic offerings, the firm is actively engaged in precision medicine initiatives, collaborating with biopharmaceutical partners to streamline drug discovery and identify novel candidates for complex neurological pathologies. This dual-pronged approach—combining clinical diagnostic utility with high-value research partnerships—positions Amprion as a cornerstone entity in the evolving landscape of neurological healthcare.
How much funding has Amprion raised?
Amprion has raised a total of $15M across 1 funding round:
Series B
$15M
Series B (2024): $15M with participation from Lilly and Formation Venture Engineering
Key Investors in Amprion
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. It focuses on areas such as diabetes, oncology, immunology, and neuroscience, serving patients across international markets through research-driven innovation.
Formation Venture Engineering
Formation Venture Engineering employs a hands-on, de-risked venture investing approach focused on the deep sciences, particularly in life sciences technologies. The company aims to empower scientists and reduce human suffering by nurturing game-changing technologies and optimizing for accelerated exits through strategic investments.
What's next for Amprion?
With the infusion of recent capital, Amprion is well-positioned to scale its commercial operations and deepen its biopharma collaborations. The strategic focus will likely shift toward expanding the clinical adoption of its biomarker assays and accelerating the development of its pipeline for additional neurodegenerative conditions. As the company moves into this next phase of enterprise-level growth, it will leverage its unique intellectual property to set new standards in precision medicine. Investors and industry stakeholders are closely monitoring how these resources will be deployed to enhance diagnostic accuracy and reduce the time-to-market for life-saving neurological therapies, ultimately reinforcing Amprion's status as a critical player in the global biotech ecosystem.
See full Amprion company page
